Total Funding
26
64
Total FundingPre-Seed raised
Growth Score
-30 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
87548
bYoRNA is cost-efficient, scalable bioproduction of high-quality therapeutic mRNA using eukaryotic cells, particularly recombinant yeast.
- Thierry Ziegler: Co-Founder
About the Company
bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared to
traditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
